Allakos (ALLK) Competitors $0.23 +0.00 (+1.69%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+0.13%) As of 03/27/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALLK vs. CLYM, VIGL, ZURA, IVVD, SLS, ACOG, ANL, RANI, CABA, and VTGNShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Climb Bio (CLYM), Vigil Neuroscience (VIGL), Zura Bio (ZURA), Invivyd (IVVD), SELLAS Life Sciences Group (SLS), Alpha Cognition (ACOG), Adlai Nortye (ANL), Rani Therapeutics (RANI), Cabaletta Bio (CABA), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Climb Bio Vigil Neuroscience Zura Bio Invivyd SELLAS Life Sciences Group Alpha Cognition Adlai Nortye Rani Therapeutics Cabaletta Bio Vistagen Therapeutics Climb Bio (NASDAQ:CLYM) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Does the media favor CLYM or ALLK? In the previous week, Climb Bio had 7 more articles in the media than Allakos. MarketBeat recorded 9 mentions for Climb Bio and 2 mentions for Allakos. Allakos' average media sentiment score of 0.97 beat Climb Bio's score of 0.61 indicating that Allakos is being referred to more favorably in the news media. Company Overall Sentiment Climb Bio Positive Allakos Positive Is CLYM or ALLK more profitable? Climb Bio's return on equity of -42.21% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -42.21% -41.39% Allakos N/A -140.87%-86.22% Which has more risk & volatility, CLYM or ALLK? Climb Bio has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Do institutionals & insiders believe in CLYM or ALLK? 69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 16.1% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, CLYM or ALLK? Climb Bio is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$35.12M-$2.13-0.60AllakosN/AN/A-$185.70M-$1.32-0.18 Does the MarketBeat Community believe in CLYM or ALLK? Allakos received 181 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformClimb BioOutperform Votes2100.00% Underperform VotesNo VotesAllakosOutperform Votes18358.84% Underperform Votes12841.16% Do analysts rate CLYM or ALLK? Climb Bio presently has a consensus price target of $10.00, indicating a potential upside of 687.40%. Allakos has a consensus price target of $2.00, indicating a potential upside of 752.15%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryAllakos beats Climb Bio on 8 of the 15 factors compared between the two stocks. Remove Ads Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.17M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.127.2024.5919.03Price / SalesN/A225.82383.9393.17Price / CashN/A65.6738.1634.64Price / Book0.126.476.944.33Net Income-$185.70M$141.90M$3.20B$247.06M7 Day Performance-6.57%-3.02%-2.30%-0.53%1 Month Performance-16.42%-4.63%3.07%-3.74%1 Year Performance-81.66%-8.61%11.15%1.72% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.6164 of 5 stars$0.23+1.7%$2.00+752.2%-81.7%$21.17MN/A-0.12190Short Interest ↓Positive NewsCLYMClimb Bio3.0045 of 5 stars$1.32+1.5%$10.00+657.6%N/A$88.74MN/A-0.629Earnings ReportNews CoverageVIGLVigil Neuroscience3.9605 of 5 stars$1.90+0.5%$16.25+755.3%-40.9%$88.68MN/A-0.9240Short Interest ↓Positive NewsZURAZura Bio2.1872 of 5 stars$1.35-2.9%$15.80+1,070.4%-41.6%$88.15MN/A0.003Earnings ReportAnalyst ForecastNews CoverageIVVDInvivyd3.6039 of 5 stars$0.72-1.9%$7.89+989.4%-84.8%$86.60M$25.38M-0.37100Analyst ForecastShort Interest ↓Gap DownSLSSELLAS Life Sciences Group0.4053 of 5 stars$1.23+2.5%N/A+12.6%$86.57M$1M-1.7810Earnings ReportPositive NewsACOGAlpha Cognition2.1387 of 5 stars$5.33-0.7%$20.00+275.2%N/A$85.39MN/A-2.08N/AUpcoming EarningsAnalyst UpgradeNews CoveragePositive NewsGap UpANLAdlai Nortye2.5021 of 5 stars$2.30+4.1%$9.00+291.3%-74.8%$84.87M$5M0.00127Short Interest ↓Positive NewsGap UpRANIRani Therapeutics3.035 of 5 stars$1.47-5.2%$12.33+739.0%-55.8%$84.22MN/A-1.39110News CoverageCABACabaletta Bio1.9625 of 5 stars$1.72-1.1%$22.71+1,220.6%-90.6%$84.07MN/A-0.8050VTGNVistagen Therapeutics1.9758 of 5 stars$2.91+4.3%N/A-42.5%$83.99M$698,000.00-1.9740 Remove Ads Related Companies and Tools Related Companies Climb Bio Competitors Vigil Neuroscience Competitors Zura Bio Competitors Invivyd Competitors SELLAS Life Sciences Group Competitors Alpha Cognition Competitors Adlai Nortye Competitors Rani Therapeutics Competitors Cabaletta Bio Competitors Vistagen Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
